In an increasingly crowded and competitive pharmaceutical landscape, where breakthroughs in active ingredients are becoming harder to achieve and efficacy differences between therapies are narrowing, the art and science of drug formulation have emerged as a decisive competitive advantage. No longer merely a technical requirement for drug delivery, formulation has evolved into a strategic imperative, shaping patient adherence, convenience, tolerability, and overall delivery efficiency. This article delves into how pharmaceutical companies are leveraging advanced formulation to stand out, drive market preference, and enhance patient outcomes in a dynamic global market.
n
The Evolving Market Dynamics: Beyond the Active Ingredient
n
For decades, the pharmaceutical industry’s focus revolved primarily around the discovery of novel active pharmaceutical ingredients (APIs) and their mechanisms of action. Success was largely defined by a drug’s intrinsic efficacy in clinical trials. However, the modern therapeutic market presents a different reality. The proliferation of similar drugs, the rise of biosimilars and generics, and shared scientific advancements mean that differentiation can no longer rest solely on the shoulders of the active molecule.
n
The main facts underscore this shift: formulation now dictates whether a therapy seamlessly integrates into clinical workflows, aligns with patient routines, streamlines pharmacy operations, and supports long-term treatment patterns. For prescribers, the critical assessment moves beyond a drug’s performance in a controlled clinical setting to its reliability and usability in real-world practice. For manufacturers, formulation and process choices are pivotal commercial decisions influencing launch performance, lifecycle management, and brand resilience. This trend is particularly pronounced in high-stakes therapeutic areas such as oncology, immunology, metabolic diseases, central nervous system (CNS) disorders, and paediatrics, where competition is fierce and incremental gains in efficacy are often marginal. In these categories, a superior formulation can elevate a product from being clinically acceptable to clinically preferred, fundamentally altering its market trajectory.
n
A Chronology of Innovation: How Formulation’s Role Has Grown
n
The journey of pharmaceutical formulation reflects a chronological evolution, from basic delivery systems designed for bioavailability to sophisticated platforms engineered for patient-centricity and strategic market advantage. Historically, formulation was often an afterthought, primarily focused on ensuring the drug reached its target site safely and effectively. Early innovations concentrated on overcoming solubility challenges, protecting sensitive APIs, and establishing basic dosage forms like tablets and capsules.
n
Over time, as scientific understanding of pharmacokinetics and pharmacodynamics deepened, and as patient compliance became recognized as a critical factor in treatment success, formulation began to take on a more nuanced role. The development of controlled-release systems in the mid-20th century marked a significant step, allowing for extended drug action and reduced dosing frequency. The late 20th and early 21st centuries saw an acceleration of innovation, driven by advancements in materials science, nanotechnology, and biotechnology. This era ushered in complex injectable formulations, transdermal patches, and orally disintegrating tablets, each designed to address specific patient needs or therapeutic challenges.
n
Today, the "chronology" of formulation innovation is characterized by a proactive, integrated approach. Formulation is no longer a downstream process but an upstream consideration, deeply intertwined with drug discovery and development strategy. The increasing complexity of biologics, the demand for personalized medicine, and the emphasis on improving quality of life for patients have pushed formulation science into a strategic leadership position. This evolution reflects a growing understanding that true innovation encompasses not just what a drug does, but how it is experienced by the patient and integrated into the broader healthcare ecosystem.
n
Unpacking the Data: Evidence of Formulation’s Impact Across Therapeutic Areas
n
The tangible benefits of advanced formulation are clearly demonstrated across various therapeutic areas, supported by market data and clinical outcomes.
n
Oncology: Precision, Efficiency, and Patient Experience
n
In oncology, formulation innovation directly addresses two paramount priorities: enhancing the patient experience and alleviating pressure on healthcare system capacity. The rapid expansion of advanced therapies, such as antibody-drug conjugates (ADCs), exemplifies the need for sophisticated delivery. According to GlobalData, the number of active ADCs nearly tripled from 557 in 2020 to 1,643 in 2025. In such a competitive arena, delivery profile and tolerability are paramount differentiators.
n
- n
- n
ADC Innovation: Linker Chemistry and Encapsulation Technologies: Differentiation within ADCs is becoming increasingly sophisticated. Linker chemistry is particularly critical, as it determines the precise timing and location of payload release. A linker that degrades too early can lead to systemic toxicity, while one that is too stable can compromise efficacy. Achieving this delicate balance is crucial for competitive performance among next-generation ADCs. Beyond linkers, technologies like liposomal encapsulation offer another route to differentiation. By encasing cytotoxic agents in lipid bilayers, biodistribution can be altered, circulation time prolonged, and exposure to healthy tissues significantly reduced. Similarly, nanoparticle delivery platforms provide comparable advantages, particularly where toxicity limits dosing intensity, making formulation central to expanding the therapeutic window through improved usability and potency.
n
- n
The IV-to-SC Shift: Nivolumab and Beyond: A transformative shift in oncology has been enabled by technologies like recombinant human hyaluronidase, facilitating the transition from lengthy intravenous (IV) infusions to minutes-long subcutaneous (SC) injections. This innovation not only frees up valuable clinic capacity but also dramatically improves patient convenience. An IV biologic typically demands infusion chairs, dedicated specialist nursing time, extensive pharmacy preparation, and prolonged patient appointments. A subcutaneous alternative can reduce administration time to mere minutes, potentially enabling home or near-home care. The FDA approval of subcutaneous nivolumab in late 2024 serves as a powerful example of this model’s rapid integration into mainstream oncology. This shift holds significant commercial weight, as convenience increasingly influences prescribing behaviour when multiple branded therapies offer broadly comparable clinical outcomes. Moreover, a therapy that reduces chair time, nursing burden, and pharmacy workload delivers substantial operational value beyond its clinical profile.
n
n
n
n
Chronic Disease Management: Boosting Adherence and Reducing Burden
n
Adherence remains one of the most formidable commercial and clinical obstacles in chronic disease management, particularly when dosing is frequent, administration is inconvenient, or side effects accumulate over time.
n
- n
- n
Oral Biologics and GLP-1s: A Game Changer: Oral formulations can broaden prescribing eligibility, simplify administration, and mitigate treatment hesitancy. In the realm of biologics and GLP-1 therapies, the shift from injectable to oral solid dosage forms represents a significant reduction in treatment burden, potentially expanding usage among patients earlier in their treatment pathways.
n
- n
Extended-Release and Long-Acting Formulations: Innovations like extended-release formulations, long-acting injectables, and microsphere-based systems can transform daily treatment regimens into monthly or even quarterly administrations. This significantly strengthens adherence in chronic conditions where persistence is a major commercial challenge, directly impacting long-term patient outcomes and market share.
n
n
n
Specialized Populations: Pediatric and Geriatric Care
Developing medicines for children and older adults presents unique formulation challenges that cannot be addressed by simply scaling down adult doses.
-
Addressing Unique Challenges: Taste, Swallowing, and Dosing Flexibility: Paediatric drug development necessitates careful consideration of age-related differences in drug absorption, metabolism, and elimination, alongside practical factors such as swallowing ability, taste preferences, motor skills, and caregiver involvement. Acceptability is paramount, as children may reject solid dosage forms or react strongly to a medicine’s flavour, colour, texture, or mouthfeel. Similarly, older patients often face challenges with swallowing large pills or managing complex regimens. Oral liquids are vital for both paediatric and geriatric populations due to ease of swallowing, flexible dosing capabilities, and rapid onset of action.
-
The Science of Acceptability: Taste Masking and Excipient Selection: Taste masking is often commercially material, particularly for orally disintegrating tablets, suspensions, and liquids that expose patients to unpleasant active pharmaceutical ingredients (APIs). Options include sophisticated flavour and sweetener systems, coating and encapsulation technologies, cyclodextrin complexation, and ion-exchange resins. However, this convenience hinges on detailed formulation science. Stability against chemical and physical degradation, microbial contamination, sedimentation, and phase separation must be meticulously managed. Excipients, preservatives, antioxidants, and chelating agents must be rigorously tested for compatibility with the API and the target patient population. In paediatrics, excipient selection is especially sensitive, as certain sweeteners, ethanol, or coating materials may be unsuitable for specific children. Viscosity and rheology also critically affect usability and dose consistency; a liquid that is too thick may be difficult to swallow and require multiple rinses, while one that is too thin may separate or lead to dosing inaccuracies. Unit-dose packaging, re-dispersible suspensions, validated dosing components, and compatible containers are crucial to mitigate these risks, making the formulation inseparable from its container, measuring device, and real-world conditions of use. Furthermore, formulations suitable for gastric and naso-gastric tubes are essential for these vulnerable populations.
Enhancing Tolerability: The Cornerstone of Long-Term Persistence
The focus on patient acceptability directly leads to a broader commercial question: can a formulation make treatment easier to start, tolerate, and sustain over time?
-
Reducing Side Effects: GLP-1s and Gastrointestinal Burden: Patients rarely discontinue an effective therapy due to doubts about its efficacy. More often, treatment persistence is undermined by tolerability issues, inconvenience, or day-to-day burden. A survey of patients who discontinued GLP-1 receptor agonists revealed that 64.4% reported feeling sick, and 45.4% experienced vomiting. Delivery systems that modify release kinetics, alter absorption pathways, or reduce local gastrointestinal exposure can significantly improve tolerability. Enteric coatings, lipid-based formulations, and modified-release technologies help reduce irritation, nausea, or gastric burden.
-
Injection Comfort: The Citrate-Free Movement: In immunology, the industry-wide adoption of citrate-free formulations has materially improved the injection experience for self-administered biologics. While reducing injection-site pain might seem like an incremental formulation adjustment, commercially, it can foster significant brand loyalty. For patients who have been self-injecting for years or even decades, enhanced comfort becomes an integral part of the product’s value proposition, directly translating to higher adherence and sustained market share.
Industry Responses and Implications: Shaping the Future of Pharma
The strategic imperative of formulation has prompted significant responses from the pharmaceutical industry, influencing R&D investment, market access strategies, and operational models.
Lifecycle Management: Protecting and Extending Brand Value
Not all formulation advantages are patient-facing. For instance, cold-chain dependence creates significant operational complexity across distribution, pharmacy handling, storage, and patient mobility. Products that maintain room-temperature stability can simplify logistics, reduce costs, and improve geographic reach, especially in emerging markets or decentralised care settings. From a manufacturing perspective, stability also dictates packaging requirements, shelf-life economics, inventory flexibility, and distribution resilience. For self-administered biologics, this flexibility enhances quality of life, removing barriers for patients who travel frequently or lack reliable refrigeration infrastructure.
Stability enhancements are also a core component of broader lifecycle management strategies. As products approach patent expiry, reformulation offers a powerful tool to extend differentiation and preserve market share. This can involve improving tolerability, introducing new routes of administration, developing more convenient delivery devices, creating taste-masked paediatric versions, offering oral liquid presentations, or converting immediate-release formulations to extended-release versions. For incumbent brands, reformulation provides a strategic bridge beyond patent expiry, migrating patients to a more convenient, tolerable, or stable version before generic or biosimilar competition intensifies, thereby safeguarding revenue streams and market position.
Operational Efficiency and Global Reach: Beyond the Cold Chain
The pharmaceutical industry’s response to formulation challenges also involves a concerted effort to enhance operational efficiency. Formulations that require less stringent storage conditions (e.g., room temperature stability) can drastically reduce supply chain costs and complexity. This is particularly relevant for global health initiatives and reaching underserved populations where cold chain infrastructure is limited or unreliable. The ability to distribute a drug more widely and efficiently translates directly into improved patient access and commercial reach. Furthermore, formulations that simplify administration reduce the burden on healthcare professionals, allowing for more efficient use of clinical resources and potentially lowering overall healthcare costs.
The Strategic Imperative of CDMO Partnerships
As formulation complexity continues to escalate, gaps in in-house capabilities within many pharmaceutical companies become more pronounced. Highly engineered delivery systems demand specialised expertise spanning sterile processing, containment, complex injectables, advanced excipients, nanoparticle handling, analytical validation, device integration, and commercial scale-up. This reality underscores the growing importance of strategic partnerships with Contract Development and Manufacturing Organisations (CDMOs).
-
Bridging Capability Gaps: Expertise, Technology, and Scale: The oral liquid pathway alone exemplifies the breadth of capabilities required. Developers need comprehensive pre-formulation studies, solubility and stability screening, taste masking, viscosity control, excipient compatibility testing, dose uniformity evaluation, packaging assessment, process validation, and reproducible scale-up. Because these requirements span both development and manufacturing, early formulation choices directly influence shelf-life, packaging strategy, technology transfer, and commercial robustness. CDMOs possess the specialized infrastructure, scientific talent, and regulatory experience to navigate these complexities efficiently, offering speed to market and mitigating significant R&D risks for their clients.
-
Piramal Pharma Solutions: A Model for Integrated Formulation and Manufacturing Support: Piramal Pharma Solutions stands as an exemplary model in meeting this critical need for integrated formulation and manufacturing support. With six specialist facilities globally (two in the US, one in the UK, and three in India), Piramal offers a diverse array of services, including process development, clinical supply, commercial manufacturing, and packaging. The company is uniquely equipped to develop, scale up, and commercialize paediatric formulations across multiple dosage forms, including oral liquids, suspensions, seal-coated pellets, chewable tablets, and creams. Noteworthy examples include their creative formulation development for paediatric mini-tablets and taste-masking of a high-dose orally disintegrating tablet, illustrating the practical problem-solving required to balance acceptability, dose flexibility, and manufacturability for challenging populations.
-
The CDMO as a Strategic Collaborator: Piramal’s comprehensive CDMO model reinforces its role as a strategic collaborator, extending across drug discovery solutions, process and pharmaceutical development services, clinical trial supplies, commercial API supply, and finished dosage forms. Their specialized capabilities include handling highly potent APIs, antibody-drug conjugations, sterile fill/finish, peptides, potent solid oral drug products, and biologics development and manufacturing through Yapan Bio, Piramal Pharma Limited’s associate company. This breadth of expertise transforms the role of the CDMO. Sponsors increasingly seek partners capable of supporting translational scale-up, formulation optimization, commercial manufacturability, regulatory readiness, and lifecycle evolution. This is especially relevant in fast-moving categories where speed to market and differentiated delivery can determine commercial outcomes. In this context, the strategic question for pharmaceutical companies is no longer simply whether a partner has capacity, but whether it possesses the scientific, technical, and operational depth to transform a complex product into one that is manufacturable, usable, and commercially resilient.
Conclusion: Formulation as the Linchpin of Modern Pharmaceutical Success
In conclusion, the pharmaceutical industry has reached an inflection point where formulation is no longer a secondary consideration but a primary strategic driver. As differences in intrinsic efficacy continue to narrow, the ability to deliver a drug in a manner that enhances patient adherence, convenience, and tolerability becomes paramount. From extending patent life and improving market access to reducing healthcare burdens and directly impacting patient quality of life, sophisticated formulation is the linchpin of modern pharmaceutical success. The strategic partnership with specialized CDMOs, equipped with integrated capabilities and deep scientific expertise, is becoming essential for companies aiming to navigate this complex landscape and secure a lasting competitive edge in the pursuit of better patient outcomes. The future of pharmaceutical innovation will undoubtedly be shaped by those who master not just the discovery of new medicines, but also the art and science of how those medicines are delivered to the world.
References:
[i] GlobalData, Antibody-Drug Conjugate Drug Landscape, 2026 report
[ii] PMC, NCBI. "Non-adherence to GLP-1 receptor agonists in patients with type 2 diabetes: a retrospective study in a real-world setting." Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017.
